AB

Bibliografia publikacji pracowników
Państwowej Szkoły Wyższej w Białej Podlaskiej

Baza tworzona przez Bibliotekę Akademii Bialskiej im. Jana Pawła II.


Zapytanie: GURIANOV VITALIY
Liczba odnalezionych rekordów: 2



Przejście do opcji zmiany formatu | Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie
1/2
Nr opisu: 0000042228
Autorzy: Oleksandr Oliynyk, Wojciech Barg, Anna Ślifirczyk, Yanina Oliynyk, Serhij Dubrov, Vitaliy Gurianov, Marta Rorat.
Tytuł pracy: Comparison of the Effect of Unfractionated Heparin and Enoxaparin Sodium at Different Doses on the Course of COVID-19 Associated Coagulopathy
Tytuł czasopisma:
Szczegóły: 2021, Vol. 11, issue 10, article number 1032
p-ISSN: 2075-1729
Charakterystyka formalna: artykuł w czasopiśmie zagranicznym
Charakterystyka merytoryczna: artykuł oryginalny naukowy
Charakterystyka wg MNiSW: artykuł w czasopiśmie z IF (wykaz MEiN)
Język publikacji: ENG
Wskaźnik Impact Factor ISI: 3.251
Punktacja ministerstwa: 70.000
Słowa kluczowe ang.: anticoagulant therapy ; blood coagulation ; respiratory failure ; SARS-CoV-2
https://www.mdpi.com/2075-1729/11/10/1032
DOI: 10.3390/life11101032
Streszczenie: COVID-19-associated coagulopathy (CAC) exacerbates the course of coronavirus infection and contributes to increased mortality. Current recommendations for CAC treatment include the use of low-molecular weight heparins (LMWH) at prophylactic or therapeutic doses, as well as the use of unfractionated heparin (UFH). Methods: A randomised, controlled trial enrolled 126 patients hospitalised in the intensive care unit with severe COVID-19 complicated by CAC. The effects of LMWH at preventive and therapeutic doses and UFH at therapeutic doses on mortality and intubation rates were compared. Results: The number of intubations and deaths showed no significant difference depending on the anticoagulant therapy used. However, multivariate logistic regression models revealed an increased risk of intubation (p = 0.026, odds ratio (OR) = 3.33, 95% confidence interval (CI) 1.15-9.59), and an increased risk of death (p = 0.046, OR = 3.01, 95% CI 1.02-8.90), for patients treated with LMWH at a prophylactic dose but not at a therapeutic dose as compared to patients treated with UFH when controlling for other risk factors. Conclusions: The use of unfractionated heparin in the treatment of COVID-19-associated coagulopathy seems to be more effective at reducing the risk of intubation and death than enoxaparin at prophylactic doses.

2/2
Nr opisu: 0000041755
Autorzy: Oleksandr Oliynyk, Wojciech Barg, Anna Ślifirczyk, Yanina Oliynyk, Vitaliy Gurianov, Marta Rorat.
Tytuł pracy: Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome
Tytuł czasopisma:
Szczegóły: 2021, Vol. 13, issue 6, article number 1067
p-ISSN: 1999-4915
Charakterystyka formalna: artykuł w czasopiśmie zagranicznym
Charakterystyka merytoryczna: artykuł oryginalny naukowy
Charakterystyka wg MNiSW: artykuł w czasopiśmie z IF (wykaz MEiN)
Język publikacji: ENG
Wskaźnik Impact Factor ISI: 5.818
Punktacja ministerstwa: 100.000
Słowa kluczowe ang.: monoclonal antibodies ; ARDS ; cytokine strom syndrome ; inflammation
Inne bazy podające opis:
  • Scopus

    https://www.mdpi.com/1999-4915/13/6/1067
    DOI: 10.3390/v13061067
    Streszczenie: Background: Cytokine storm in COVID-19 is heterogenous. There are at least three subtypes: cytokine release syndrome (CRS), macrophage activation syndrome (MAS), and sepsis. Methods: A retrospective study comprising 276 patients with SARS-CoV-2 pneumonia. All patients were tested for ferritin, interleukin-6, D-Dimer, fibrinogen, calcitonin, and C-reactive protein. According to the diagnostic criteria, three groups of patients with different subtypes of cytokine storm syndrome were identified: MAS, CRS or sepsis. In the MAS and CRS groups, treatment results were assessed depending on whether or not tocilizumab was used. Results: MAS was diagnosed in 9.1% of the patients examined, CRS in 81.8%, and sepsis in 9.1%. Median serum ferritin in patients with MAS was significantly higher (5894 vs. 984 vs. 957 ng/mL, p < 0.001) than in those with CRS or sepsis. Hypofibrinogenemia and pancytopenia were also observed in MAS patients. In CRS patients, a higher mortality rate was observed among those who received tocilizumab, 21 vs. 10 patients (p = 0.043), RR = 2.1 (95% CI 1.0-4.3). In MAS patients, tocilizumab decreased the mortality, 13 vs. 6 patients (p = 0.013), RR = 0.50 (95% CI 0.25-0.99). Conclusions: Tocilizumab therapy in patients with COVID-19 and CRS was associated with increased mortality, while in MAS patients, it contributed to reduced mortality.

      Wyświetl ponownie stosując format:
    • Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka AB